1 – 2 of 2
      - show: 10
 - |
 - sort: year (new to old)
 
        Close
        
            
    
    Embed this list
<iframe src=""
              width=""
              height=""
              allowtransparency="true"
              frameborder="0">
            </iframe>
        - 2024
 - 
                        Mark
        Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
    
    
- Contribution to journal › Article
 
 - 2023
 - 
                        Mark
        Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe : The SCHOLAR-2 retrospective chart review study
    
    
- Contribution to journal › Article